Secondary endpoint

Definition

A secondary endpoint is an outcome measure that a clinical trial evaluates in addition to the primary endpoint. Secondary endpoints typically provide supporting evidence about the effects of a treatment on related outcomes. For example, if the primary endpoint is weight loss, secondary endpoints might include changes in body fat percentage, changes in muscle mass, changes in blood pressure, and changes in metabolic markers. Secondary endpoints are pre-specified in the study protocol but are not required to show statistical significance for the treatment to be considered successful. However, if the treatment demonstrates significant benefits on clinically relevant secondary endpoints, this strengthens the overall evidence base and may support regulatory approval or clinical use. Secondary endpoints are particularly valuable when they measure different aspects of treatment effect or when they evaluate safety and tolerability. In research peptide studies, secondary endpoints commonly include pharmacokinetic measurements, biomarker changes, safety assessments, and quality-of-life measures.

Secondary endpoints serve several purposes: they demonstrate that treatment effects are not limited to the primary endpoint but extend to related clinical outcomes; they provide mechanistic insight into how the treatment works; and they identify potential adverse effects or safety concerns. Analysis of secondary endpoints is exploratory; findings are interpreted with caution because multiple comparisons increase the risk of false-positive findings due to chance. Trends in secondary endpoint data can generate hypotheses for future studies but are not considered definitive evidence.

Regulators use secondary endpoint data to assess the overall benefit-risk profile of a treatment. A treatment might meet criteria for approval based on the primary endpoint alone, but strong secondary endpoint data supporting improved quality of life, reduced hospitalisation, or better safety profile strengthens the case for approval. Conversely, if secondary endpoints show unexpected adverse effects, regulators may impose restrictions on use or require additional monitoring.